ondansetron has been researched along with Pancreatic Neoplasms in 6 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
Pancreatic Neoplasms: Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of the study was to evaluate the role of ramosetron for the prevention of chemoradiotherapy-induced nausea and vomiting (CRINV) in patients receiving upper abdominal irradiation with concurrent 5-fluorouracil chemotherapy." | 7.75 | Ramosetron for the prevention of nausea and vomiting during 5-fluorouracil-based chemoradiotherapy for pancreatico-biliary cancer. ( Bang, YJ; Chie, EK; Ha, SW; Im, SA; Jang, JY; Kim, K; Kim, SW; Kim, TY; Oh, DY, 2009) |
| "The aim of the study was to evaluate the role of ramosetron for the prevention of chemoradiotherapy-induced nausea and vomiting (CRINV) in patients receiving upper abdominal irradiation with concurrent 5-fluorouracil chemotherapy." | 3.75 | Ramosetron for the prevention of nausea and vomiting during 5-fluorouracil-based chemoradiotherapy for pancreatico-biliary cancer. ( Bang, YJ; Chie, EK; Ha, SW; Im, SA; Jang, JY; Kim, K; Kim, SW; Kim, TY; Oh, DY, 2009) |
| "Case 3, a 44-year-old woman, having breast cancer treated with 5-fluorouracil, cyclophosphamide, and epirubicin developed an MPR after the second chemotherapy treatment." | 1.35 | Cutaneous adverse drug reactions during chemotherapy: consider non-antineoplastic drugs. ( Barbaud, A; Bursztejn, AC; Cuny, JF; Schmutz, JL; Tréchot, P, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (50.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, K | 1 |
| Chie, EK | 1 |
| Jang, JY | 1 |
| Kim, SW | 1 |
| Oh, DY | 1 |
| Im, SA | 1 |
| Kim, TY | 1 |
| Bang, YJ | 1 |
| Ha, SW | 1 |
| Bousquet, PJ | 1 |
| Co-Minh, HB | 1 |
| Demoly, P | 1 |
| Bursztejn, AC | 1 |
| Tréchot, P | 1 |
| Cuny, JF | 1 |
| Schmutz, JL | 1 |
| Barbaud, A | 1 |
| Ishizuka, J | 1 |
| Hsieh, AC | 1 |
| Townsend, CM | 1 |
| Thompson, JC | 1 |
| Delahunt, JW | 1 |
| Burgess, C | 1 |
| Bott, V | 1 |
| Jacobsen, MB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase III Prospective Randomized Trial Comparing Ramosetron Versus Ondansetron for Radiotherapy Induced Nausea and Vomiting in the Treatment of Gastrointestinal Cancer[NCT00971399] | Phase 3 | 172 participants (Anticipated) | Interventional | 2009-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 other studies available for ondansetron and Pancreatic Neoplasms
| Article | Year |
|---|---|
Ramosetron for the prevention of nausea and vomiting during 5-fluorouracil-based chemoradiotherapy for pancreatico-biliary cancer.
Topics: Adult; Aged; Antiemetics; Benzimidazoles; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Female; F | 2009 |
Isolated urticaria to ondansetron and successful treatment with granisetron.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Drug Hypersensitivity; Granisetr | 2005 |
Cutaneous adverse drug reactions during chemotherapy: consider non-antineoplastic drugs.
Topics: Adult; Antiemetics; Antineoplastic Agents; Breast Neoplasms; Cross Reactions; Drug Eruptions; Female | 2008 |
Effect of 5-HT3 receptor antagonist (ondansetron) on functioning human pancreatic carcinoid cells.
Topics: Calcium; Carcinoid Tumor; Cell Division; Cyclic AMP; Dose-Response Relationship, Drug; Humans; Hydro | 1993 |
Ondansetron and VIPoma.
Topics: Adult; Humans; Male; Nausea; Ondansetron; Pancreatic Neoplasms; Vipoma | 1993 |
Ondansetron in carcinoid syndrome.
Topics: Aged; Carcinoid Tumor; Humans; Imidazoles; Male; Ondansetron; Pancreatic Neoplasms; Serotonin Antago | 1992 |